Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Nuvalent, Inc. (NASDAQ:NUVL) have received a consensus recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and fifteen have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $138.3333.

Several equities research analysts recently weighed in on NUVL shares. JPMorgan Chase & Co. decreased their target price on Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. The Goldman Sachs Group boosted their price objective on shares of Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Leerink Partners increased their target price on shares of Nuvalent from $140.00 to $149.00 and gave the company an “outperform” rating in a research report on Monday, November 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a research note on Thursday, January 22nd. Finally, Guggenheim upped their price objective on shares of Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th.

Insiders Place Their Bets

In related news, insider Deborah Ann Miller sold 14,300 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $110.16, for a total value of $1,575,288.00. Following the completion of the sale, the insider directly owned 59,634 shares of the company’s stock, valued at $6,569,281.44. This represents a 19.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Henry E. Pelish sold 2,664 shares of Nuvalent stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $97.17, for a total value of $258,860.88. Following the transaction, the insider directly owned 65,888 shares in the company, valued at approximately $6,402,336.96. This trade represents a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 76,463 shares of company stock worth $7,722,489. Corporate insiders own 10.20% of the company’s stock.

Institutional Trading of Nuvalent

Several institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its position in Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after purchasing an additional 108 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Nuvalent during the third quarter worth about $38,000. Eastern Bank purchased a new position in shares of Nuvalent during the third quarter worth about $52,000. Persistent Asset Partners Ltd acquired a new position in Nuvalent in the 2nd quarter valued at about $88,000. Finally, CWM LLC increased its position in Nuvalent by 253.8% in the 2nd quarter. CWM LLC now owns 1,486 shares of the company’s stock valued at $113,000 after acquiring an additional 1,066 shares during the period. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent Price Performance

Nuvalent stock opened at $104.95 on Friday. The stock has a market cap of $7.63 billion, a PE ratio of -19.73 and a beta of 1.32. The stock’s fifty day moving average is $103.41 and its two-hundred day moving average is $94.73. Nuvalent has a 1-year low of $55.53 and a 1-year high of $113.01.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.